Short answer
Adaptive Biotechnologies Corp (ADPT) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 contains only a non-incorporation disclaimer.
Adaptive Biotechnologies Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 contains only a non-incorporation disclaimer
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $70.9M, up 35% YoY; MRD drove $67.1M and 95% of total revenue
- MRD growth accelerated 53% with clonoSEQ volume up 41% to 32,595 tests
- MRD Adjusted EBITDA reached $12.1M versus $(4.1)M, signaling improving segment economics
- Immune Medicine revenue fell 57% to $3.8M and Adjusted EBITDA loss widened to $10.4M
- 2026 MRD guidance raised to $260M–$270M; cash, equivalents and securities totaled $237.2M at March 31
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Adaptive Biotechnologies Corp 8-K filings
Get the next ADPT 8-K as it lands
Follow ADPT for push alerts, or ask the research agent what this filing means.